Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

share, compared to a net loss of $42.2 million, or $0.96 per share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008, a $4.4 million decrease in research and development expenses related to KRX-0401, and a $21.1 million increase in license revenue related to an amendment to the September 2007 sublicense agreement with JT/Torii ($18.0 million), as discussed above, and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009.

Commenting on the quarter, Ron Bentsur, the Company's Chief Executive Officer, remarked, "Keryx has made significant progress over the last few months. We presented important Phase 2 data on both our compounds, regained full compliance with the listing requirements of the Nasdaq Capital Market, and announced our SPA for the Phase 3 trial of perifosine in multiple myeloma. We look forward to finalizing our discussions with the FDA regarding the U.S. Phase 3 program for Zerenex shortly, at which time Keryx will be in the compelling position of having two Phase 3 compounds." Mr. Bentsur added, "I am excited by the opportunity to transform Keryx into a late-stage development company and maximize shareholder value. On behalf of the entire Keryx team, I want to thank all of our shareholders for their continued support."

On Thursday, August 6, 2009, at 8:30am EDT, the Company will host an investor conference call during which they will provide a brief financial overview of the Company's second quarter financial results and a business outlook for the remainder of 2009.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
(Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
(Date:1/14/2014)... Panama (PRWEB) January 14, 2014 ... received the county’s first clinical trial approval for ... cord-derived mesenchymal stem cells (MSC) from the Comité ... Board (IRB). , Rheumatoid Arthritis (RA) is an ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... Sept. 8 /PRNewswire-FirstCall/,-- Concuity, a healthcare division ... a leading,provider of contract management and revenue ... today announced that Valley Baptist Health,System has ... more,accurately calculate payments from managed care and ...
... (Nasdaq: CTICD ; and MTA: CTIC) announced ... Listing Qualifications Staff of The NASDAQ Stock,Market LLC ... with the,$50,000,000 minimum market value of listed securities ... the Company does not,comply with NASDAQ Marketplace Rule ...
... Just as test pilots push planes to explore ... Standards and Technology (NIST) are probing the newest ... the nanoscale. Better nanoscale measurements are critical for ... and nanomanufacturing industries. , This new microscope technology ...
Cached Biology Technology:Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 3Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 4CTI Receives NASDAQ Letter 2CTI Receives NASDAQ Letter 3NIST studies how new helium ion microscope measures up 2
(Date:7/9/2014)... Sexual selection refers to species, selection for traits that ... of natural selection enhances opportunities to mate, the tail ... at the University of California, Riverside have now found ... a placenta are linked. Describing the life histories ... family Poeciliidae, the researchers found that species with placentas ...
(Date:7/9/2014)... (TCGA) Research Network have identified novel mutations in ... most common subtype of lung cancer. Knowledge of ... possible therapeutic targets for this disease and potentially ... mutations because many potent cancer drugs that target ... funded and managed by the National Cancer Institute ...
(Date:7/9/2014)... With grilling season upon us, many backyard cooks are ... fatty hot dogs. But low fat can sometimes mean ... addressing the texture problem in low-fat wieners that are ... study was published in ACS, Journal of Agricultural ... colleagues note that hot-dog consumers have come to expect ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... those hoping to start or extend a family should ... Current clinical guidelines already recommend that women who are ... based on the knowledge that cholesterol is essential for ... the risk of congenital anomalies in children of pregnant ...
... pollution are decreasing the growth of trees in the northern ... in Global Change Biology . Tree growth, measured ... and this is set to increase to a 17% reduction ... four times greater now than prior to the Industrial Revolution ...
... momentum of,September,s impressive showing at the ePassports EAC Conformity ... advances its role as the,world,s ePassport leader by being ... advanced second-generation ePassports based on the,Extended Access Control (EAC) ... ePassports represent the beginning of an evolution that,will improve ...
Cached Biology News:Statin warning for pregnant women 2Surface-level ozone pollution set to reduce tree growth 10 percent by 2100 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 3The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 4
... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 50 minigels. A 1 mL unit size ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
... RSH-4000 is the only microplate sealer with ... long walkaway times with a variety of ... Fully automated with integrated stacker and 240-plate ... EX for use in small workcells , ...
... Reagents for the differentiation of mouse embryonic ... bodies exist in the midbrain, where they ... the ventral tegmental area, and the retrorubral ... to extensive forebrain dopamine innervation ( e.g.projections ...
Biology Products: